Roy et al. developed an enzyme prodrug therapy based on upconverting NPs and photo-cross-linkable anti-EGFR Afbs (UC-ACD) [227], leading to a 4-fold higher retention in irradiated colorectal cancer cells in vitro (Figure 8). This evidence concerns the gene EGFR and colorectal cancer.